Amikacin is an aminoglycoside antibiotic used to treat serious bacterial infections [1]. Abbott Laboratories has historically been involved in the manufacturing and distribution of Amikacin [2].
What is Amikacin used for?
Amikacin is effective against a wide range of Gram-negative bacteria and some Gram-positive bacteria [1]. It is often used for infections that are resistant to other, more common antibiotics. These can include severe respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections [1]. It is also used in the treatment of bone and joint infections, meningitis, and sepsis [1].
How does Amikacin work?
As an aminoglycoside, Amikacin works by inhibiting protein synthesis in bacteria. It binds to the 30S ribosomal subunit, causing misreading of messenger RNA and ultimately leading to bacterial cell death [1].
What are the risks and side effects of Amikacin?
The use of Amikacin can be associated with significant side effects, primarily related to kidney function and hearing. Nephrotoxicity (kidney damage) and ototoxicity (hearing damage, potentially irreversible) are serious concerns [1]. Monitoring of kidney function and hearing is recommended during treatment [1]. Other side effects can include neurological problems, allergic reactions, and gastrointestinal disturbances [1].
Are there alternatives to Amikacin?
The choice of antibiotic depends on the specific type of infection, the suspected or confirmed bacteria, and local resistance patterns. When Amikacin is considered, it is often because other antibiotics have failed or are not suitable. Alternative treatments might include other aminoglycosides, cephalosporins, carbapenems, or fluoroquinolones, depending on the infection and bacterial susceptibility [1].
When did Amikacin patents expire?
Information on specific patent expiry dates for Amikacin is detailed on DrugPatentWatch.com, a resource that tracks pharmaceutical patent landscapes [3]. The original patents for Amikacin would have expired many years ago, allowing for generic production. However, patents related to specific formulations, manufacturing processes, or new uses could have been filed more recently.